These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19001322)

  • 21. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations.
    Caiata-Zufferey M; Pagani O; Cina V; Membrez V; Taborelli M; Unger S; Murphy A; Monnerat C; Chappuis PO
    Genet Med; 2015 Sep; 17(9):726-32. PubMed ID: 25503500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
    Francken AB; Schouten PC; Bleiker EM; Linn SC; Rutgers EJ
    Breast; 2013 Oct; 22(5):561-8. PubMed ID: 23972475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    McCarthy AM; Bristol M; Domchek SM; Groeneveld PW; Kim Y; Motanya UN; Shea JA; Armstrong K
    J Clin Oncol; 2016 Aug; 34(22):2610-8. PubMed ID: 27161971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
    Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
    Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    Kurian AW; Li Y; Hamilton AS; Ward KC; Hawley ST; Morrow M; McLeod MC; Jagsi R; Katz SJ
    J Clin Oncol; 2017 Jul; 35(20):2232-2239. PubMed ID: 28402748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
    Adams I; Christopher J; Williams KP; Sheppard VB
    J Cancer Educ; 2015 Jun; 30(2):344-52. PubMed ID: 25301325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation.
    Narod SA; Butler R; Bobrowski D; Akbari MR; Curling D; Lunn J; Ho C; Panahi S; Llacuachaqui M; Donenberg T; Hurley J
    Mol Genet Genomic Med; 2018 Mar; 6(2):301-304. PubMed ID: 29266833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
    Armstrong K; Weber B; Stopfer J; Calzone K; Putt M; Coyne J; Schwartz JS
    Am J Med Genet A; 2003 Mar; 117A(2):154-60. PubMed ID: 12567413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together.
    Demarco TA; Nusbaum RH; Peshkin BN; Patenaude AF; Schneider KA; Garber JE; Valdimarsdottir HB; Tercyak KP
    Patient Educ Couns; 2010 Jan; 78(1):29-33. PubMed ID: 19545972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-to-patient BRCA1 testing: the Twoj Styl experience.
    Gronwald J; Huzarski T; Byrski T; Debniak T; Metcalfe K; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2006 Dec; 100(3):239-45. PubMed ID: 16807675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
    Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.